Activation fees

No definition available.

Name:	psnl_ActivationFees
Namespace Prefix:	psnl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Class of warrant or right, expense recognized.

+ References

No definition available.

+ Details

Name:	psnl_ClassOfWarrantOrRightExpenseRecognized
Namespace Prefix:	psnl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Fair market value of promotional and commercialization services

+ References

No definition available.

+ Details

Name:	psnl_FairMarketValueOfPromotionalAndCommercializationServices
Namespace Prefix:	psnl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

First milestone fee.

+ References

No definition available.

+ Details

Name:	psnl_FirstMilestoneFee
Namespace Prefix:	psnl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

First milestone payments upon achievement of specified clinical validations

+ References

No definition available.

+ Details

Name:	psnl_FirstMilestonePaymentsUponAchievementOfSpecifiedClinicalValidations
Namespace Prefix:	psnl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Increase (decrease) in fair value of warrants.

+ References

No definition available.

+ Details

Name:	psnl_IncreaseDecreaseInFairValueOfWarrants
Namespace Prefix:	psnl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Initial fair value of warrants.

+ References

No definition available.

+ Details

Name:	psnl_InitialFairValueOfWarrants
Namespace Prefix:	psnl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of Warrents

+ References

No definition available.

+ Details

Name:	psnl_NumberOfWarrents
Namespace Prefix:	psnl_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of its gross revenues attributable to such license

+ References

No definition available.

+ Details

Name:	psnl_PercentageOfItsGrossRevenuesAttributableToSuchLicense
Namespace Prefix:	psnl_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Second Milestone Fees Payable Subject to Achieving Two Additial Clinical Validations

+ References

No definition available.

+ Details

Name:	psnl_SecondMilestoneFeesPayableSubjectToAchievingTwoAdditialClinicalValidations
Namespace Prefix:	psnl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 25
-Paragraph 13
-SubTopic 10
-Topic 480
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481766/480-10-25-13

+ Details

Name:	us-gaap_FairValueAdjustmentOfWarrants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received for fees during the current period. This element excludes cash proceeds from license fees.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_ProceedsFromFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfWarrants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_WarrantsAndRightsOutstandingMaturityDate
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=psnl_TempusWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=psnl_TempusAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=psnl_FirstWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Tempus Agreement - Additional Information (Details) $ / shares in Units, $ in Thousands			12 Months Ended
	Nov. 28, 2023 USD ($) $ / shares shares	Nov. 25, 2023 USD ($)	Dec. 31, 2023 USD ($) Warrants
Tempus Warrants
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from issuance of Warrants			$ 6,000
Tempus Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Market Development Fees	$ 6,000		6,000
Activation Fees		$ 3,000	3,000
First milestone fees payment upon achivement of specified clinical validations		3,000
Second milestone fees payment subject to achieving two additional clinicial validations		6,000
Fair market value of promotional and commercialization services		9,600
First milestone fee			$ 3,000
Number of warrants \| Warrants			2
Initial fair value	6,900
Proceeds from issuance of Warrants	6,000
Increase in fair value of warrants			$ 3,100
Tempus Agreement \| Other Income (Expense)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant losses	$ 900		900
Warrant expense recognized			4,000
Tempus Agreement \| First Warrant
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant exercise price per share \| $ / shares	$ 1.5
Warrant expiration date	Dec. 31, 2024
Tempus Agreement \| Tempus Warrants
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant exercise price per share \| $ / shares	$ 2.5
Warrant expiration date	Dec. 31, 2025
Proceeds from issuance of Warrants			$ 6,000
Tempus Agreement \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Market Development Fees		$ 12,000
Percentage of its gross revenues attributable to such license			20.00%
Tempus Agreement \| Maximum \| First Warrant
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant issued to purchase stock \| shares	4,609,400
Tempus Agreement \| Maximum \| Tempus Warrants
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant issued to purchase stock \| shares	4,609,400
Tempus Agreement \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of its gross revenues attributable to such license			10.00%